<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03257033</url>
  </required_header>
  <id_info>
    <org_study_id>RR3 [CP-03-001]</org_study_id>
    <nct_id>NCT03257033</nct_id>
  </id_info>
  <brief_title>Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC</brief_title>
  <acronym>TIGeR-PaC</acronym>
  <official_title>Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenovoRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenovoRx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a multi-center, un-blinded, randomized control study of subjects with locally&#xD;
      advanced pancreatic adenocarcinoma which is unresectable.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will receive induction therapy of IV gemcitabine plus nab-paclitaxel, as well as&#xD;
      radiation therapy for approximately four months. Subjects who remain eligible will then be&#xD;
      randomized to receive either intra-arterial chemotherapy with gemcitabine; or to continue&#xD;
      gemcitabine plus nab-paclitaxel. Subjects will receive the randomized treatments for up to 16&#xD;
      weeks or until progression. Both groups will receive either IV gemcitabine and nab-paclitaxel&#xD;
      or oral capecitabine following the 16 week treatment course until disease progression at the&#xD;
      discretion of the Investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects with stable or responding disease after approximately four months of induction therapy, and who are not surgical candidates will then be randomized to be in either the test group or control group. Crossovers are not allowed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 Years</time_frame>
    <description>OS from time of randomization will be calculated using the Kaplan-Meier method and compared between the test and control groups using the stratified Log-Rank Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival for treatment received and unresected populations</measure>
    <time_frame>3 Years</time_frame>
    <description>The primary endpoint analysis will be repeated for the Treatment Received and Unresected Subject populations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 Years</time_frame>
    <description>To compare the Progression Free Survival of intra-arterial delivery of gemcitabine using the RenovoCath™ device vs. continuation of IV gemcitabine and nab-paclitaxel following induction therapy with gemcitabine and nab-paclitaxel and radiation treatment for locally advanced pancreatic adenocarcinoma. Disease response and progression will be assessed according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate and duration of response</measure>
    <time_frame>3 Years</time_frame>
    <description>Objective response is defined as a complete response, CR, or partial response, PR, determined by Investigator assessment and confirmed by repeat assessment ≥ 4 weeks after initial documentation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>3 Years</time_frame>
    <description>The EORTC questionnaire will be used to assess health related quality of life. The summary scores for the EORTC questionnaire will be calculated at baseline and follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropathy Assessment</measure>
    <time_frame>1 Year</time_frame>
    <description>The degree of neuropathy will be measured by the FACT/GOG-NTX-4 (version 4). The results will be cross tabulated by randomized treatment group for each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of neutropenia</measure>
    <time_frame>1 Year</time_frame>
    <description>Neutropenia with onset after randomization requiring the use of filgrastim or other medications for white blood cell stimulation will be compared between the test and control groups through progression of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported symptoms</measure>
    <time_frame>3 years</time_frame>
    <description>Symptoms reported by subjects using the PRO-CTCAE questionnaire will be compared between the test and control groups through progression of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, defined as adverse event rate, and tolerability, defined as occurrence of treatment discontinuation</measure>
    <time_frame>3 years</time_frame>
    <description>Safety and tolerability will be assessed by the occurrence of treatment discontinuation and the presence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Locally Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>IA Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IA Treatments with 1,000 mg/m2 gemcitabine administered through RenovoCath every other week for a maximum of 8 treatments for approximately 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV gemcitabine and nab-paclitaxel will be administered for 16 weeks on days 1, 8, and 15 of a 28 day cycle. Nab-paclitaxel will be administered intravenously following pre-medication at a dose of 125 mg/m2 over 30 minutes followed by an infusion of gemcitabine at a dose of 1000 mg/m2 over 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>IA Therapy</arm_group_label>
    <arm_group_label>IV Therapy</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>Chemotherapy</description>
    <arm_group_label>IV Therapy</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RenovoCath</intervention_name>
    <description>Intra-arterial catheter</description>
    <arm_group_label>IA Therapy</arm_group_label>
    <other_name>RenovoCath RC120</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytopathology confirmed pancreatic adenocarcinoma with initial&#xD;
             diagnosis within 6 weeks of consent&#xD;
&#xD;
          2. Locally advanced, unresectable disease at screening and prior to randomization, as&#xD;
             defined by NCCN criteria determined by an on-site, experienced, multidisciplinary team&#xD;
             (as confirmed by CT or MRI within 30 days of the first on study treatment).&#xD;
&#xD;
          3. ECOG performance status 0-1&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. Absolute neutrophil count ≥ 1,500/μL&#xD;
&#xD;
          6. Platelet count ≥ 100,000/μL&#xD;
&#xD;
          7. Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          8. Serum creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min/1.73 m2 for subjects&#xD;
             with creatinine &gt;1.5 mg/dL&#xD;
&#xD;
          9. AST and ALT ≤ 3.0 X the upper normal limit of institution's normal range&#xD;
&#xD;
         10. Prior to the initiation of the first on study treatment (Cycle 1/Day 1):&#xD;
&#xD;
               1. Total bilirubin ≤ 1.5 X the upper normal limit of institution's normal range, or&#xD;
&#xD;
               2. Total bilirubin ≤ 2.0 X the upper normal limit of institution's normal range if&#xD;
                  biliary stent placed or planned to be placed within 6 weeks of Cycle 1/Day 1&#xD;
&#xD;
         11. PT and PTT must be ≤ 1.5 X upper normal limit of institution's normal range&#xD;
&#xD;
         12. INR ≤ 1.5&#xD;
&#xD;
         13. Life expectancy &gt; 12 weeks&#xD;
&#xD;
         14. Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             within 1 day prior to administration of the first dose of chemotherapy. Women of&#xD;
             childbearing potential should only use highly effective methods of contraception&#xD;
             during treatment and for up to 6 months following treatment cessation.&#xD;
&#xD;
         15. Provide written informed consent&#xD;
&#xD;
         16. Subjects willing to participate in the study for at least 8 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any prior treatment for pancreatic cancer. If all other inclusion/exclusion criteria&#xD;
             are met, and with prior written approval from sponsor, an exception may be granted for&#xD;
             subjects who have had up to one prior treatment cycle with gemcitabine/nab-paclitaxel&#xD;
             as this regimen is standard of care and part of the initial induction treatment on the&#xD;
             protocol. For subjects who have started on first cycle of gemcitabine and&#xD;
             nab-paclitaxel treatment prior to consent, Inclusion Criterion #1 only applies in that&#xD;
             the first gemcitabine/nab-paclitaxel dose must be within six weeks of diagnosis.&#xD;
&#xD;
          2. Any evidence of metastatic disease or another active malignancy within the past one&#xD;
             year except for cervical cancer in situ, in situ carcinoma of the bladder or&#xD;
             non-melanoma carcinoma of the skin&#xD;
&#xD;
          3. Subjects unable or unwilling to have their first randomized treatment within three&#xD;
             weeks of the post induction imaging and within 5 weeks of their last induction&#xD;
             treatment&#xD;
&#xD;
          4. Subjects without baseline tumor imaging&#xD;
&#xD;
          5. Anatomy suitable for IA delivery of gemcitabine to the intended tumor site, determined&#xD;
             by CT or MRI, as determined by the sponsor, which precludes the following:&#xD;
&#xD;
               1. Stenosis or occlusion in intended artery for treatment&#xD;
&#xD;
               2. Tortuosity preventing the delivery of the guide sheath and or RenovoCath®&#xD;
                  catheter to intended site&#xD;
&#xD;
               3. Inability to exclude major side branches in the area of the intended RenovoCath®&#xD;
                  occlusion&#xD;
&#xD;
               4. No suitable artery with a diameter greater than 3mm in proximity of at least one&#xD;
                  side of the tumor Note: Suitable anatomy will be reviewed by RenovoRx Imaging&#xD;
                  Advisor after receipt of initial CT or MRI.&#xD;
&#xD;
          6. Subjects with known HIV or active viral hepatitis&#xD;
&#xD;
          7. Severe infections within 4 weeks prior to the first study treatment, including but not&#xD;
             limited to hospitalization for complications of infection, bacteremia, or severe&#xD;
             pneumonia&#xD;
&#xD;
          8. Signs or symptoms of infection within 2 weeks prior to the first study treatment&#xD;
&#xD;
          9. Received oral or IV antibiotics for an infection within 2 weeks prior to the first&#xD;
             study treatment. Subjects receiving prophylactic antibiotics are eligible.&#xD;
&#xD;
         10. History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             gemcitabine or nab-paclitaxel&#xD;
&#xD;
         11. Any anti-cancer therapy including chemotherapy, hormonal therapy, or radiotherapy&#xD;
             within 2 weeks prior to initiation of study treatment; or herbal therapy intended as&#xD;
             anti-cancer therapy within 1 week prior to initiation of study treatment&#xD;
&#xD;
         12. Subjects with uncontrolled seizures&#xD;
&#xD;
         13. Cardiovascular disease including unstable angina or life-threatening cardiac&#xD;
             arrhythmia, myocardial infarction, stroke; or New York Heart Association (NYHA) Class&#xD;
             III or IV congestive heart failure within the last 3 months prior to the first study&#xD;
             treatment. Subjects with prior history of Myocardial Infarction, congestive heart&#xD;
             failure, coronary artery bypass grafting, or prior valve surgery need to have&#xD;
             assessment of ejection fraction to ensure EF is not ≤ 40%, within last 3 months prior&#xD;
             to the first study treatment.&#xD;
&#xD;
         14. Life-threatening visceral disease, other severe concurrent disease, or comorbidities&#xD;
             which make it difficult to participate in the study&#xD;
&#xD;
         15. Any of the following procedures prior to initiation of study treatment:&#xD;
&#xD;
               1. Catheterization, endoscopy, stent or drain placement, within 48 hours, and&#xD;
                  laparoscopy without surgical intervention can be in less than 48 hours&#xD;
&#xD;
               2. Minor surgery requiring light sedation, (such as surgical laparoscopy) within 2&#xD;
                  weeks&#xD;
&#xD;
               3. Major surgery within 4 weeks&#xD;
&#xD;
         16. Women who are breastfeeding&#xD;
&#xD;
         17. Male or female subjects of reproductive potential who do not agree to employ two&#xD;
             highly effective and acceptable forms of contraception throughout their participation&#xD;
             in the study and for 6 months after last study treatment&#xD;
&#xD;
         18. Subjects receiving any other investigational agents within 2 weeks prior to the first&#xD;
             study treatment&#xD;
&#xD;
         19. Any psychiatric illness or social situations that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
         20. Subjects unable or unwilling to have standard catheterization procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Pishvaian</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins Kimmel Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Charles Li</last_name>
    <phone>6502844433</phone>
    <email>charles@renovorx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole G Lama</last_name>
    <phone>6502844433</phone>
    <email>nlama@renovorx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheba Malek</last_name>
      <phone>909-825-7084</phone>
      <phone_ext>1535</phone_ext>
      <email>sheba.malek@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Aurora Romero</last_name>
      <phone>909-825-7084</phone>
      <phone_ext>4548</phone_ext>
      <email>aurora.romero@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Mark E Reeves, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Center Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Dunn</last_name>
      <phone>916-454-6931</phone>
      <email>dunncm@sutterhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Michele Pierini</last_name>
      <phone>916-454-6994</phone>
      <email>pierinmm@sutterhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Laing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Care and Research Institute of Colorado, CCCRIC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33167</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priscilla Lopez</last_name>
      <phone>786-527-8561</phone>
      <email>PriscillaLop@BaptistHealth.net</email>
    </contact>
    <investigator>
      <last_name>Ripal Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Ucar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Health Care System</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34329</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Lacy</last_name>
      <phone>941-917-6519</phone>
      <email>Kim-lacy@smh.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Meredith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Carr</last_name>
      <phone>813-745-8446</phone>
      <email>stephanie.carr@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Cassie Nesbit</last_name>
      <phone>813-745-4584</phone>
      <email>cassie.nesbit@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nainesh Parikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASCLEPES Research Centers</name>
      <address>
        <city>Weeki Wachee</city>
        <state>Florida</state>
        <zip>34607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Leonard, BSN</last_name>
      <phone>352-364-9401</phone>
      <email>kleonard@asclepes.com</email>
    </contact>
    <investigator>
      <last_name>Daniel A Kerr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont-Columbus Regional - John B. Amos Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics - Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Arnold</last_name>
      <phone>319-356-2778</phone>
      <email>michelle-arnold@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Pashtoon Kasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>LSU Health Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lea Green</last_name>
      <phone>318-813-1058</phone>
      <email>lea.green@lsuhs.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Hoffman</last_name>
      <phone>318-813-1412</phone>
      <email>kelly.hoffman@lsuhs.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mindie Kavanaugh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medstar Franklin Square</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer A Latteri, RN</last_name>
      <phone>443-777-8289</phone>
      <email>Jennifer.A.Latteri@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Pallavi Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey M O'Quinn</last_name>
      <phone>603-653-9338</phone>
      <email>Casey.M.O'Quinn@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Eric Hoffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at Cooper Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Logan</last_name>
      <phone>856-735-6234</phone>
      <email>Logan-Amanda@CooperHealth.edu</email>
    </contact>
    <investigator>
      <last_name>Jamin Morrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System - Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Albany Stratton VA Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute - Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melani Terri, BSN</last_name>
      <phone>704-863-2318</phone>
      <email>melani.terry@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Reza Nazemzadeh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Brigham</last_name>
      <phone>252-744-4924</phone>
      <email>brighamd16@ecu.edu</email>
    </contact>
    <investigator>
      <last_name>Emmanuel Zervos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Wildman</last_name>
      <email>swildman@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Grice</last_name>
      <email>agrice@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Kouri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma University - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Yarbrough</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>48340</phone_ext>
      <email>melissa-yarbrough@ouhsc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Genie Bryant</last_name>
      <phone>(405) 271-8001</phone>
      <phone_ext>53482</phone_ext>
      <email>genie-bryant@ouhsc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hassan Hatoum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knight Cancer Institute Clinical Trial Information</last_name>
      <phone>503-494-1080</phone>
    </contact>
    <investigator>
      <last_name>Charles Lopez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Lane-Scott</last_name>
      <phone>412-864-7688</phone>
      <email>lanewg@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Amer Zureikat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina - Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Hunt</last_name>
      <phone>843-792-9778</phone>
      <email>winterl@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alan Brisendine</last_name>
      <phone>843-792-9007</phone>
      <email>brisend@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David T Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health (formerly Greenville Health System)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Williams</last_name>
      <phone>864-522-2066</phone>
      <email>kim.williams3@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Ki Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>West Virginia University Medicine</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lan Hu</last_name>
      <phone>304-293-6960</phone>
      <email>lan.hu@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Boone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Lucas</name>
      <address>
        <city>Brugge</city>
        <zip>8310</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>UZ Antwerp</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrien De Bosschere</last_name>
      <email>katrien.debosschere@azmmsj.be</email>
    </contact>
    <investigator>
      <last_name>Erik Vanderstraeten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Jolimont Hospital</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Buelens</last_name>
      <email>isabelle.buelens@jolimont.be</email>
    </contact>
    <investigator>
      <last_name>Thierry Delaunoit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann D'Hondt</last_name>
      <email>ann.dhondt@azdelta.be</email>
    </contact>
    <investigator>
      <last_name>Jochen Decaestecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2017</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

